Resistance studies of erythromycin and rifampin for Rhodococcus equi over a 10-year period

This study sought to determine whether an increase in resistance of Rhodococcus equi to the antibiotics rifampin and erythromycin occurred over a 10-year period. This was carried out by the use of E test strips for rifampin and erythromycin to determine the MIC (minimum inhibitory concentration) values of Rhodococcus equi to this combination of antibiotics.The findings of this study indicated that there was an increase in resistance of Rhodococcus equi to rifampin and erythromycin over the 10-year period. The MIC for rifampin increased from 0.081 μg/ml in 1996 to 0.187 μg/ml in 2006 and from 0.258 μg/ml for erythromycin during the years prior to 2000 to 0.583 μg/ml in 2006.This finding suggests that there may be a problem in the treatment of Rhodococcus equi infections in foals in the future, particularly as the number of drugs available for treatment of Rhodococcus equi infection is limited because of the intracellular capabilities of this bacterium. Antibiotics used in its treatment have to be able to penetrate the polysaccharide cell wall of Rhodococcus equi as well as the alveolar macrophages in which the bacterium is capable of surviving.     

猪链球菌对红霉素耐药性的研究

从发病猪体内分离、鉴定猪链球菌，采用肉汤稀释法和纸片琼脂扩散法筛选对红霉素耐药的猪链球菌，用双纸片法确定耐药株的耐药表型，通过聚合酶链反应检测对红霉素耐药的基因ermb/mefA。猪链球菌对红霉素的耐药表型为cMLS表型，即同时对克林霉素耐药。在3株红霉素耐药株中扩增到ermb基因，其余未能检测到ermb或mefA基因。     

Bioencapsulation of five forms of erythromycin by adult Artemia salina (L.)

Uptake of five chemical forms of erythromycin by adult Artemia salina (L.) (erythromycin phosphate – EP, erythromycin stearate – ES, erythromycin estolate – EE, erythromycin hydrate – EH and crystalline erythromycin – CE) was investigated in two trials. In each trial, final erythromycin concentration in Artemia tissue and survival after a 12‐h bioencapsulation period were determined. In the first trial, Artemia tissue concentration after a 12‐h bioencapsulation period was significantly (P < 0.05) affected by erythromycin form with ES (68.5 ± 3.3 μg mL^?1, mean ± SEM) ≈ EH (61.2 ± 3.4 μg mL^?1) > CE (37.1 ± 10.7 μg mL^?1) > EP (16.4 ± 7.7 μg mL^?1) > control. In trial 2, Artemia tissue concentration was also significantly (P < 0.05) affected by erythromycin form with EE (111.4 ± 9.6 μg mL^?1) > CE (89.1 ± 1.7 μg mL^?1) > ES (78.9 ± 1.6 μg mL^?1) > EP (33.4 ± 5.2 μg mL^?1) > control. Survival was significantly affected by erythromycin form in trial 1 with EP=control (100 ± 0.0%) > ES (74.4 ± 2.0%) > CE (32.2 ± 0.3%) > EH (8.8 ± 4.4%). In trial 2, survival was also significantly affected by erythromycin form with EP=control (100 ± 0.0%) > ES (67.1 ±3.7%) > CE (52.5 ± 7.7%) > EE (5.0 ± 2.5%). Based on both uptake and survival, EP and ES appear to be appropriate compounds for bioencapsulation of erythromycin using live adult Artemia.     

Erythromycin and florfenicol treatment of rainbow trout Oncorhynchus mykiss (Walbaum) experimentally infected with Flavobacterium psychrophilum

Flavobacterium psychrophilum is responsible for significant economic losses in rainbow trout aquaculture. Antimicrobial treatment remains the primary means of control; however, there are limited choices available for use. The objectives of the study were therefore to determine the minimum inhibitory concentrations for erythromycin and florfenicol in selected F. psychrophilum isolates and to evaluate their clinical treatment efficacy in experimentally infected rainbow trout. All isolates tested had moderate susceptibility to florfenicol and erythromycin except one isolate, which had low susceptibility to erythromycin. Two isolates (one with moderate and one with low susceptibility to erythromycin) were used in an experimental infection trial. Rainbow trout juveniles were injected intraperitoneally with 10⁸ cfu/fish and after mortality had begun, fish were given erythromycin‐ and florfenicol‐medicated feed at a rate of 75 mg kg^?1 day^?1 and 10 mg kg^?1 day^?1 fish body weight, respectively, for 10 consecutive days. The splenic F. psychrophilum load was determined using an rpoC quantitative PCR throughout the 30‐day trial. Relative to antibiotic‐free controls, erythromycin treatment significantly (p < 0.05) reduced mortality of rainbow trout juveniles infected with FPG101, even when treatment was initiated after clinical signs developed.     

泰拉霉素和红霉素对一氧化氮和前列腺素E2合成抑制作用的比较

目的以红霉素为对照,探讨泰拉霉素是否具有抗炎作用。方法利用细菌脂多糖(LPS)诱导猪外周血单核细胞(PBMC)过度表达致炎因子而构建的体外炎症模型,采用SYBR Green法实时荧光定量PCR技术,在分子水平研究了不同浓度泰拉霉素和红霉素对一氧化氮(NO)和前列腺素E2(PGE2)合成的影响。结果20μg·mL-1和10μg·mL-1浓度的泰拉霉素与20、10和5μg·mL-1浓度的红霉素均能显著抑制猪PBMC细胞合成NO和PGE2,并抑制诱导型一氧化氮合成酶(iNOS)和环氧合酶-2(COX-2)基因的转录;而5μg·mL-1的泰拉霉素无明显的这种调节作用。结论泰拉霉素和红霉素能在转录和翻译水平通过调节致炎因子的合成而发挥抗炎作用。     

复方硫氰酸红霉素可溶性粉对人工感染鸡慢性呼吸道病的疗效试验

用复方硫氰酸红霉素可溶性粉以每升水中加0.5、0.6、0.7、0.8、0.9 g 5个剂量对人工感染鸡慢性呼吸道病的鸡群混饮治疗,同时设立硫氰酸红霉素可溶性粉对照组.试验结果表明,用药5d后,复方硫氰酸红霉素可溶性粉每升水加0.6、0.7、0.8、0.9g剂量组的有效率和治愈率皆高于硫氰酸红霉素可溶性粉组.     

Interactions between erythromycin,flunixin meglumine,levamisole and plant secondary metabolites towards bovine gastrointestinal motility—in vitro study

Continued ingestion of plant secondary metabolites by ruminants can provoke pharmacological interactions with pharmaceutical agents used in animals. As some drugs and phytocompounds affect smooth muscle activity, the aim of this study was to verify the possible interaction between selected pharmaceutical agents and plant secondary metabolites towards bovine gastrointestinal motility. The interactions between phytocompounds—apigenin, quercetin, hederagenin, medicagenic acid—and medicines—erythromycin, flunixin meglumine and levamisole—were evaluated on bovine isolated abomasal and duodenal specimens obtained from routinely slaughtered cows. The obtained results confirmed the contractile effect of all three drugs used solely. Hederagenin and medicagenic acid (0.001 μM) enhanced the contractile effect of levamisole. Hederagenin additionally increased the impact of erythromycin. Both saponins (100 μM) showed synergistic effects with all tested pharmaceuticals. Apigenin and quercetin (0.001 μM) intensified the contractile response induced by erythromycin and levamisole. Moreover, both flavonoids (100 μM) showed an antagonistic interaction with all tested drugs which in that situation were devoid of the prokinetic effect. To conclude, plant metabolic metabolites such as saponins and flavonoids are potent modifiers of the effect of drugs towards gut motility. The synergy observed between phytocompounds and selected medicines can be beneficial in the treatment of cows with hypomotility disorders.     

星点设计-效应面法优化硫氰酸红霉素肺靶向明胶微球的配方

用星点设计-效应面法优化硫氰酸红霉素明胶微球的处方,以期得到分散性好、粒径符合要求的明胶微球。本研究采用乳化-化学交联法制备,以明胶浓度、油水比例、乳化剂浓度为自变量,微球的平均粒径、载药量、包封率、跨距为因变量对自变量的各水平进行多元线性回归和二项式拟合。根据因变量效应面法选取较佳工艺,并在此基础上制备了硫氰酸红霉素微球,且进行了优化处方的验证。结果显示,二项式模型拟合效果较多元线性回归要好,最佳优化处方为明胶浓度0.156g/mL、油水比例12∶2、乳化剂浓度0.03g/mL,根据优化工艺制备的微球分散性好,平均粒径、载药量、跨距、包封率分别为12.51μm、21.28%、1.51和84.39%。体外释药特性研究表明,该微球符合一级方程规律,具有明显的缓释效果。通过星点设计-效应面法成功建立了处方优化模型,且预测性良好。     

红霉素与四环素耐药基因在猪链球菌临床分离株中的检测

为了解临床分离的48株猪链球菌对大环内酯类药物及四环素耐药基因的分布,用微量稀释法测定48株临床分离的猪链球菌对大环内酯类、四环素、β-内酰胺类及头孢类9种抗生素的药物敏感性,建立PCR方法对耐药菌株大环内酯类耐药基因ermA/B/C、mefA/E、msrD、mphB、23S rRNA,L4,L22和四环素耐药基因tetM、tetO、tetL、tetK及与Tn916转座子相关的int和xis基因进行检测。结果表明,31株2型猪链球菌中大环内酯类药物耐药率为3.23%,17株9型猪链球菌红霉素耐药率为88.24%,泰乐菌素、磷酸替米考星、阿奇霉素的耐药率均为70.59%。48株猪链球菌对四环素均耐药,但对青霉素、阿莫西林、头孢曲松钠、氨苄西林均敏感。大环内酯类耐药基因主要以ermB为主,占75%(12/16),mefA/E、msrD占25%(4/16),16株红霉素耐药菌株中,tetM、tetO、int、xis的检出率分别为25%(4/16)、62.5%(10/16)、31.25%(5/16)和31.25%(5/16),没有检测到ermA、ermC、mphB、tetL、tetK。所有红霉素耐药菌株均未检测到23S rRNA、L4和L22突变。     

复方特比萘芬纳米乳的制备及其含量测定

【目的】研制复方特比萘芬纳米乳,并对其含量进行测定。【方法】以特比萘芬、丁香酚和红霉素为供试药物,通过绘制伪三元相图筛选复方特比萘芬纳米乳处方,利用透射电子显微镜(TEM)、Nicomp 388/Zeta PALS激光粒度测定仪分别考察其形态和粒径,采用染色法鉴别纳米乳的类型,利用高效液相色谱法对其含量测定方法进行研究。【结果】复方特比萘芬纳米乳最佳配方中各组分的质量分数分别为：特比萘芬1.3%,丁香酚2.5%,红霉素1.3%,吐温-80 24%,无水乙醇12%,肉豆蔻酸异丙酯2%,蒸馏水56.9%。透射电镜下,复方特比萘芬纳米乳呈圆球形,无粘连;其平均粒径(Z-Average)为11.9 nm,多分散系数(PDI)为0.06。另外还建立了精确测定复方特比萘芬纳米乳3种主药含量的高效液相色谱法。【结论】复方特比萘芬纳米乳制备工艺简单,稳定性良好且质量可控,有望应用于宠物临床。